PMID- 20831513
OWN - NLM
STAT- MEDLINE
DCOM- 20151030
LR  - 20231105
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 70
IP  - 5
DP  - 2010 Nov
TI  - Emerging treatment options for type 2 diabetes.
PG  - 631-44
LID - 10.1111/j.1365-2125.2010.03711.x [doi]
AB  - Type 2 diabetes mellitus (T2DM) is rapidly increasing in prevalence and is a 
      major public health problem. It is a progressive disease which commonly requires 
      multiple pharmacotherapy. Current options for treatment may have undesirable side 
      effects (particularly weight gain and hypoglycaemia) and contraindications, and 
      little effect on disease progression. Incretin based therapy is one of several 
      newer therapies to improve glycaemia and is available in two different forms, 
      dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) 
      agonists. Use of these agents results in a 'glucose-dependant' increase in 
      insulin secretion and glucagon suppression resulting in improved glycaemia with 
      low incidence of hypoglycaemia. DPP-4 inhibitors are oral drugs which are weight 
      neutral, while GLP-1 agonists are injected subcutaneously and help promote weight 
      loss while improving glycaemia. GLP-1 agonists have also been shown to increase 
      beta cell mass in rat models. Bariatric surgery is another option for the obese 
      patient with T2DM, with blood glucose normalizing in over half of the patients 
      following surgery. Other therapies in development for the treatment of T2DM 
      include sodium-glucose transporter 2 (SGLT-2) inhibitors, glucagon receptor 
      antagonists, glucokinase activators and sirtuins. In this article, we will review 
      the various existing and emerging treatment options for T2DM.
CI  - (c) 2010 Schwarz Biosciences GmbH, UCB-Group. Journal compilation (c) 2010 Blackwell 
      Publishing Ltd.
FAU - Piya, Milan K
AU  - Piya MK
AD  - Department of Diabetes and Endocrinology, Heart of England NHS Foundation Trust, 
      Birmingham, UK. Centre for Endocrinology, Diabetes and Metabolism, School of 
      Clinical and Experimental Medicine, College of Medical and Dental Sciences, 
      University of Birmingham, Birmingham, UK.
FAU - Tahrani, Abd A
AU  - Tahrani AA
FAU - Barnett, Anthony H
AU  - Barnett AH
LA  - eng
GR  - RTF/01/094/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Animals
MH  - Bariatric Surgery
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Glucagon-Like Peptide 1/*agonists
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Incretins/*metabolism
MH  - Obesity/complications/metabolism/prevention & control
MH  - *Sodium-Glucose Transporter 2 Inhibitors
PMC - PMC2997303
EDAT- 2010/09/14 06:00
MHDA- 2015/10/31 06:00
PMCR- 2011/11/01
CRDT- 2010/09/14 06:00
PHST- 2010/09/14 06:00 [entrez]
PHST- 2010/09/14 06:00 [pubmed]
PHST- 2015/10/31 06:00 [medline]
PHST- 2011/11/01 00:00 [pmc-release]
AID - 10.1111/j.1365-2125.2010.03711.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2010 Nov;70(5):631-44. doi: 
      10.1111/j.1365-2125.2010.03711.x.